Gut hormones as therapeutic agents in treatment of diabetes and obesity

被引：42
|
作者：
Tan, Tricia [1 ]
Bloom, Stephen [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Div Diabet Endocrinol & Metab, Dept Investigat Med, London W12 0HS, England
来源：
CURRENT OPINION IN PHARMACOLOGY | 2013年 / 13卷 / 06期
基金：
英国生物技术与生命科学研究理事会; 英国医学研究理事会;
关键词：
GLUCAGON-LIKE PEPTIDE-1; HIGH-FAT DIET; GASTRIC BYPASS-SURGERY; FOOD-INTAKE; BARIATRIC SURGERY; ENERGY-EXPENDITURE; WEIGHT-LOSS; PANCREATIC-POLYPEPTIDE; INSULIN-RESISTANCE; EXENATIDE TWICE;
D O I：
10.1016/j.coph.2013.09.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Obesity and Type 2 Diabetes Mellitus (T2DM) present an ever-increasing threat to global health. Although bariatric surgery is an effective treatment, it cannot be applied to the vast majority of patients. The beneficial effects of bariatric surgery are related to complex alterations in the secretion of gut hormones. By recapitulation of the changes of gut hormone secretion after bariatric surgery, drugs based on gut hormones represent an exciting possibility for the treatment of T2DM and obesity. We review the rapidly emerging role of GLP-1 based treatments as well as the future for new drugs based on other gut hormones such as GIP, ghrelin, oxyntomodulin and peptide YY.
引用
收藏
页码：996 / 1001
页数：6
相关论文
共 50 条
  • [21] Incretin hormones, obesity and gut microbiota
    Angelini, Giulia
    Russo, Sara
    Mingrone, Geltrude
    PEPTIDES, 2024, 178
  • [22] Are gut hormones related to obesity in offspring?
    Guo, Jiun-Yu
    Chen, Chih-Yen
    NUTRITION, 2021, 84
  • [23] Obesity, Gut Hormones, and Bariatric Surgery
    Pournaras, Dimitrios J.
    le Roux, Carel W.
    WORLD JOURNAL OF SURGERY, 2009, 33 (10) : 1983 - 1988
  • [24] Therapeutic potential of antiangiogenic agents for prevention and treatment of obesity
    Cao, Yihai
    Cao, Renhai
    Xue, Yuan
    FUTURE LIPIDOLOGY, 2008, 3 (02): : 153 - 162
  • [25] THE USE OF HORMONES AS THERAPEUTIC AGENTS
    ZALOGA, GP
    CHERNOW, B
    SEMINARS IN RESPIRATORY MEDICINE, 1985, 7 (01): : 39 - 51
  • [26] Gut Microbiota and Obesity: Potential Therapeutic Targets and Probiotic Treatment
    White, Nicole D.
    AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2016, 10 (02) : 104 - 106
  • [27] Genistein: A promising therapeutic agent for obesity and diabetes treatment
    Behloul, Nouredine
    Wu, Guanzhong
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 698 (1-3) : 31 - 38
  • [28] Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
    De Silva, Akila
    Bloom, Stephen R.
    GUT AND LIVER, 2012, 6 (01) : 10 - 20
  • [29] PANCREATIC AND GUT HORMONES IN STARVATION DIABETES
    HENRY, RW
    ARDILL, J
    BUCHANAN, KD
    DIABETOLOGIA, 1975, 11 (04) : 349 - 349
  • [30] The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus
    Kootte, R. S.
    Vrieze, A.
    Holleman, F.
    Dallinga-Thie, G. M.
    Zoetendal, E. G.
    de Vos, W. M.
    Groen, A. K.
    Hoekstra, J. B. L.
    Stroes, E. S.
    Nieuwdorp, M.
    DIABETES OBESITY & METABOLISM, 2012, 14 (02): : 112 - 120
12345